Arrival of CAR-T Immunotherapy Raise Hopes for Treatment and Anxieties About Costs – Cancer Therapy Advisor
Cancer Therapy Advisor |
Arrival of CAR-T Immunotherapy Raise Hopes for Treatment and Anxieties About Costs
Cancer Therapy Advisor In the phase 2 trial of 63 patients upon which FDA approval was based, CTL019 boasted a remarkable 83% overall remission rate, raising hopes that this immunotherapy could represent a much-needed option for patients with relapsed/refractory ALL. |
